Objective. The podocyte lesion in LN is still an intriguing controversy. We assess the associations between podocyte lesions and clinico-pathological features in a large cohort of LN patients.
Various factors could induce the podocyte injury. Regardless of the different causes of podocyte injury, the characteristic response in morphology is the effacement of podocyte foot processes [1] . The multiple underlying pathogenesis in LN offers a unique challenge to fully understand the functions of the podocyte in general [2] .
There were increasing reports of LN patients with apparent podocyte injury that was identical to minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS). Most of research held that this phenomenon was not a coincidental event [311] and a new pathological entity called lupus podocytopathy was proposed to describe a subset of proteinuric LN patients without evidence of typical immune complex deposits vs extensive podocyte effacement [3, 12, 13] . The phenomenon indicated that the overt proteinuria occurring in LN might involve pathways related to podocyte injury other than classical immune complex deposition. Furthermore, it should be recognized that renal podocyte damage might also contribute to the pathogenesis and progression of other types of LN, which needs further investigation.
In this study we performed a detailed morphometric analysis of podocyte foot processes in LN patients to assess the associations between podocyte lesions and clinical, laboratory and pathological features in a large cohort of Chinese patients with LN.
Materials and methods

Patients
Clinico-histopathological data of 202 patients with renal biopsy-proven LN diagnosed between January 2000 and July 2008 in the Peking University First Hospital were retrospectively reviewed. The patients fulfilled the 1997 ACR revised criteria for SLE [14] .
Clinical assessment
The criteria for systemic involvement was consistent with the 1997 ACR revised criteria for SLE [14] . The clinical disease activity was assessed using the SLEDAI [15, 16] . The response to therapy includes complete remission, partial remission and treatment failure, detailed in previous works [1719] . The patients were followed up in outpatient clinics specified for LN. The primary endpoint was defined as death and the secondary endpoint was defined as end-stage renal disease (ESRD) or a doubling of serum creatinine.
Informed consent was obtained for blood sampling and renal biopsy from each patient. The research was in compliance with the Declaration of Helsinki. The study was approved by the ethics committee of the Peking University First Hospital, Beijing.
Laboratory assessment
Serum ANA and anti-dsDNA antibodies were detected using IFF (EUROIMMUN, Lü beck, Germany). Anti-ENA antibodies were detected using an immunodotting assay (EUROIMMUN). aCL antibodies were detected using ELISA (EUROIMMUN). Serum C3 was determined using a rate nephelometry assay (IMMAGE, Beckman-Coulter, Brea, CA, USA; normal range >0.85 g/l).
Renal histopathology
The renal biopsy specimens were examined by light microscopy, direct IF and EM techniques. All of the patients were classified according to the ISN/RPS (2003) LN classification [20] . Pathological parameters such as activity indices and chronicity indices were determined by renal pathologists using a previously reported system involving semi-quantitative scoring of specific biopsy features [21, 22] . Podocytopathy in LN has been defined in previous studies [3, 5, 13] . Biopsy findings revealed either no glomerular immune deposits or sparse deposits, which were mainly confined to the glomerular mesangium. The characteristic pathological glomerular abnormality was extensive effacement of podocyte foot processes ultrastructurally.
Morphometric analysis of foot process width
Foot process width (FPW) was used to assess the podocyte effacement. For each picture under EM, the GBM was traced and measured using Scandium analysis software (Olympus, Mü nster, Germany). The number of podocyte foot processes along the GBM was counted by hand. Measurements were made only in capillary loops. A foot process was defined as any connected epithelial segment butting on the basement membrane between two neighbouring filtration pores or slits. From each patient, the arithmetic mean of the FPW was calculated as follow:
where AE foot process is the total number of foot processes counted in pictures of each patient, AE GBM length is the total GBM length measured in pictures of each patient and the correction factor 4 serves to correct for presumed random variation in the angle of section relative to the long axis of the podocyte [23, 24] . The intra-observer variability of the FPW was assessed by the coefficient of variation (the ratio of the S.D. to the mean) between two measurements of the same object by one observer [23] . The inter-observer variability in this study was assessed by the intraclass correlation coefficient (ICC) [25, 26] .
Statistical analysis
Statistical analysis was performed using SPSS 13.0 software (IBM, Armonk, NY, USA). Data were expressed as mean (S.D.) or median [interquartile range (IQR)] or ratio. Differences between groups were determined by Student's t-test, one-way analysis of variance (ANOVA) and non-parametric tests. Correlation analysis was performed using Spearman's rank test. Survival analysis was performed using the Cox regression. Receiver operating characteristics (ROC) curves were used to determine the most discriminative threshold for FPW in predicting nephrotic syndrome. Reliability analysis was performed to test the ICC between two observers. Differences were considered significant when P < 0.05.
Results
General data
The age of the 202 patients at the time of renal biopsy was 33.1 years (S.D. 11.5, range 1490). The male-to-female ratio was 1:6. The detailed general clinical and pathological data are not shown. The general clinico-pathological data of the 202 LN patients are shown in supplementary Foot process effacement in LN In our study, one observer randomly measured the FPW of five LN patients and the ratios of the S.D. to the mean were 3.09%, 4.56%, 5.35%, 7.75% and 7.82%, respectively, which were all <10%. This indicated good intravariability agreement. Two observers independently measured the FPW of 10 LN patients and the ICC between the two observers was 0.907 (>0.8), which indicated good interobserver agreement.
The median FPW was 1397 nm (range 6268253) in the 202 patients, which was significantly higher than the normal range in our centre [ Thirteen patients, including nine with minimal change glomerulopathy pattern injury and four with focal and segmental glomerulosclerosis pattern injury, met the histological criteria of lupus podocytopathy, reflected by an FPW of 1366 nm (IQR 12102055 nm) (Fig. 2D ). Details of the 13 patients are shown in Table 1 .
Repeated kidney biopsy was carried out in eight patients. Although FPW changed accordingly with the disease activity, especially proteinuria, in some patients the value of FPW decreased at the disease remission phase (patients 5, 6 and 8), in some the value of the FPW increased at the disease relapsing phase (patients 2 and 7), while the other three patients (1, 3 and 4) did not present with significant consistency between FPW and disease activity (details in Table 2 ).
Correlation analysis of FPW with clinical, laboratory and pathological parameters in LN As the FPW presented with abnormal distribution in the study, the correlations between FPW and continuous variables were performed using Spearman's rank correlation test. Among the clinical and pathological parameters, only proteinuria, serum creatinine, age and haemoglobin level were continuous variables, and the scatter plots of these are shown in supplementary Fig. S1ad , available at Rheumatology Online. The correlations between FPW and other ordinal variables were also performed using Spearman's rank correlation test.
We found that the FPW was significantly correlated with the levels of proteinuria (r = 0.509, P < 0.001). ROC curve analysis showed that the most applicable cut-off value, >1240 nm, could differentiate nephrotic proteinuria from non-nephrotic proteinuria with a sensitivity of 81.5% and a specificity of 62.7%. The selections of the above indices were based on the following: the area under the curve was 0.76 (95% CI 0.693, 0.827, P < 0.001), which indicated moderate accuracy, and the highest Youden's index was 0.442 on the curve.
Since the mechanism of renal podocyte injury might be distinct in different types of LN, we divided the patients into three groups: proliferative LN (pure class III and class IV), membranous LN (pure class V), and combined LN (class III + V and class IV + V).
In the proliferative LN group, the FPW was positively correlated with the level of proteinuria (r = 0.508, P < 0.001), serum creatinine (r = 0.223, P = 0.021) and most of the renal pathological indices, including cellular crescents (r = 0.209, P = 0.032), interstitial inflammatory (r = 0.311, P = 0.001), total chronicity index (r = 0.261, P = 0.007), tubular atrophy (r = 0.303, P = 0.002) and interstitial fibrosis (r = 0.240, P = 0.013).
In the membranous LN and combined groups, the FPW was significantly correlated with proteinuria (r = 0.387, P = 0.011 and r = 0.473, P = 0.004, respectively) and serositis (r = 0.326, P = 0.035 and r = 0.355, P = 0.034, respectively). No correlations were found between the FPW and other parameters. All the above correlation coefficients are shown in Table 3 .
Treatments and renal outcomes of patients with severe podocyte fusion Since an FPW >1240 nm could differentiate nephrotic proteinuria from non-nephrotic proteinuria, we evaluated the treatment algorithm and renal outcomes of these patients with severe podocyte fusion. In the 128 patients enrolled, all completed induction treatment with oral prednisone (0.81 mg/kg/day or equivalents for 46 weeks and tapered gradually to a maintenance dose of 510 mg/day). Eighty-nine patients received monthly i.v. CYC (600800 mg/month) for at least 6 consecutive months, eight patients received MMF, five patients received LEF, ) www.rheumatology.oxfordjournals.org received tacrolimus. In total, 56 patients achieved complete remission, 49 patients had partial remission and 23 patients had treatment failure. Based on different treatment regimens, we divided these into two groups (Table  4) : group 1 was 102 patients with CYC, MMF or LEF; group 2 was 26 patients with calcineurin inhibitors ciclosporin A or tacrolimus. With further comparisons we found that the proportion of complete remission was significantly higher in group 2 than in group 1 (65.4% vs 38.2%, P = 0.011), while the proportions of partial remission and treatment failure were not significantly different. The cumulative incidences of the first complete remission, partial remission and total remission are shown in Fig.  3ac . Most patients in the two groups used angiotensinconverting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) and blood pressure was well controlled and there was no significant difference between the two groups (data not shown).
During a similar follow-up time (average for nearly 5 years) there was no significant difference between the two groups regarding long-term renal survival, although it seemed that group 2 had a better renal outcome [P = 0.657, hazard ratio (HR) = 0.706, 95% CI 0.152, 3.277). Using the log-rank test for univariate survival analysis of renal prognosis in all 202 patients with LN, we found that the FPW was not a risk factor for renal outcome (P = 0.217).
Discussion
The LN classification proposed by the ISN/RPS in 2003 was based on glomerular lesions and has been widely used. Few descriptions of podocyte lesions were mentioned in the system, although podocytes play an important role in various glomerular diseases. Most previous studies about podocyte lesions in LN were mainly focused on mesangial LN, which was called lupus podocytopathy [3, 4, 7] . However, a comprehensive investigation of clinico-pathological features of podocyte injury in LN was still needed. Here we performed a detailed morphometric analysis of podocyte foot processes to assess the associations between podocyte lesions and clinico-pathological characteristics based on the ISN/RPS classification system using a large cohort of Chinese patients with LN in our centre.
We found that the podocyte effacement was obvious in most LN patients. The FPW was positively significantly correlated with the level of proteinuria. The degree of foot process fusion varied within the pathological types of LN, in which the combined types (i.e. class III + V and class IV + V) presented with the most severe manifestations. We also found that there existed morphological diversity of podocyte lesions between the different types: e.g. in proliferative LN, the podocyte fused extensively, and in lupus membranous nephropathy, the podocytes that were close to the electron dense deposits effaced more notably. A recent study by Rezende et al. [27] indicated that staining of some podocyte-associated molecules, such as Wilms tumour protein (WT1), synaptopodin and glomerular epithelial protein 1 (GLEPP1), was better preserved in pure class V LN than in pure proliferative LN. The preserved podocyte structural architecture might account for a better long-term renal outcome. This suggested that the underlying mechanisms of podocyte lesions might be distinct between different pathological types of LN.
Thus we further analysed the correlations between the degree of podocyte foot process fusion and clinico-pathological features in different pathological groups, including proliferative LN (pure class III and class IV), membranous lupus nephropathy (pure class V) and combined LN (class III + V and class IV + V).
In the proliferative LN group, the FPW was positively correlated with renal injury characteristics, including the level of proteinuria, the value of serum creatinine and most of the renal pathological active and chronic indices. The underlying mechanisms of podocyte injury are complex in proliferative LN. Both humoral and cell-mediated immunity might be involved in the pathogenesis in the setting of a genetically susceptible population in LN [28] . The immune-complex deposition in the capillary, subepithelial and mesangial fields and subsequent aggravating inflammation response could result in podocyte injury [2] . A large number of macrophages, Th1 cells and CD40 + cells infiltrated in diffuse proliferative LN, but not in membranous LN [28] , indicating that the cell-mediated immunity might play an important role in podocyte lesions in this type. On the other hand, several autoantibodies were found to directly cross-react with podocyte proteins, like a-actinin-4 [29] , and lead to the podocyte cytoskeleton reorganization that presented with podocyte fusion morphologically in proliferative LN.
The FPW in membranous LN was wider compared with that in the proliferative group, and the foot process effaced more significantly in the places that were close to the electron dense deposits. In membranous LN, patients with overt proteinuria presented with wider FPWs than those without massive proteinuria [30] , indicating that the overt proteinuria in this type of LN might relate to dysfunctions of the podocytes. Some antigens that were expressed by podocytes (i.e. M-type phospholipase A2 receptor, neutral endopeptides) [31, 32] dominant targets of the immunological injury in primary membranous nephropathy. So we assumed that the podocytes might also provide some potential antigen targets for circulating antibodies that directly injured the podocytes or formed immune complex deposits in lupus membranous nephropathy. Immune-complex deposition and subsequent complement activation, especially the formation of the membrane attack complex (MAC), might inflict cytotoxic injury on the podocytes in lupus membranous nephropathy [33] . Both experimental animal models and studies in humans suggest that the MAC is indispensable in podocyte injury. Depletion of C6 prevented proteinuria without affecting the formation of subepithelial deposits in membranous nephropathy [34] . Urinary excretion of C5b-9 in patients with either idiopathic or lupus membranous nephropathy was higher than in other renal diseases [35] . The subsequent accumulation of reactive oxygen species may further damage podocytes. Mashmoushi et al. [36] recently found that nitric oxide can lead to podocyte lesions in LN and L-NIL (the nitric oxide synthase inhibitor) has a protective effect against proteinuria. In addition to the roles of antibodies and the complement system, the T lymphocytes, mainly Th2 cells, might also participate in the mechanism of podocyte lesions. In the MRL/lpr mouse model of proliferative LN, shifting of the Th1 to Th2 dominance converted diffuse proliferative to membranous nephritis [37, 38] . As the podocyte foot process in the combined type of LN was most severe compared with other groups, the pathogenesis might be more intricate. Multiple potent factors could damage the podocyte according to the various mechanisms mentioned above. In our study, 13 cases (6.4%) were diagnosed as lupus podocytopathy based on the strict criteria [3] , including nine with MCD and four with FSGS. The ratio was higher than in previous reports [3, 5] . On the basis of disease prevalence data, the statistical estimated probability of SLE and MCD or FSGS occurring in the same individual is <1 in 10 000 [5] , which was far lower than the true prevalence reported by two large series [3, 5] and ours. Thus most authors suggest that it is a non-coincidental link. Although the pathogenesis of idiopathic MCD or FSGS remains unclear, most scholars favour a circulating glomerular toxin hypothesis and that cytokine production of aberrant T cell function is responsible for the podocyte injury [39] . Recently some new circulating factors have been postulated to play a role in podocyte injury, including angiopoietin-like-4 (ANGPTL4) in idiopathic MCD and soluble urokinase receptor (suPAR) in idiopathic FSGS [40, 41] . Thus the pathogenesis of LN, especially a T cell cytokine-mediated process altering the expression of cellular adhesion molecules, as well as inducing B cells to produce multiple autoantibodies, and modified by genetic influences was proposed as an immunological mechanism given the association between the two conditions (i.e. LN and idiopathic podocytopathy) [42] . A recent study that focused on 19 patients with collapsing glomerulopathy and SLE indicated a genetic susceptibility association of an increased probability of the two diseases in African Americans [43] .
Since an FPW >1240 nm could differentiate nephrotic proteinuria from non-nephrotic proteinuria, we further evaluated the treatment algorithm and renal outcomes of 128 patients, including different types of LN. Based on the different therapy regimens, we divided them into two groups: one group using CYC, MMF or LEF, which mainly interfered with the synthesis of DNA or RNA to suppress the proliferation of lymphocytes, and the other group using ciclosporin A or tacrolimus, which mainly inhibited calcineurin, suppressing Ca 2+ -dependent T cell activation and subsequent cytokine release. The non-immune effect of the calcineurin inhibitor, blocking calcineurin-mediated dephosphorylation of synaptopodin and stabilizing the actin cytoskeleton of podocyte, seemed to be more important to podocyte injury [44, 45] . Interestingly, we found that the remission rate and long-term renal outcomes were both better in the group using calcineurin inhibitors, which indicated that aberrant T cell function might be partly responsible for the prominent podocyte injury in some LN. Recent studies on lupus membranous nephropathy [46] and successful treatment of class V + IV LN with multitarget therapy [47] further highlight the position of calcineurin inhibitors in the treatment of LN.
Taken together, we supposed that pure lupus podocytopathy might act as an extreme form of lupus podocyte lesions, and more patients presenting with severe podocyte effacement concealed in different types of LN should attract greater attention. As this was a retrospective work, which might limit the significance of the results, especially the treatment and follow-up data, prospective exploration is needed in the future.
Rheumatology key messages
. Podocyte damage in LN presents as lupus podocytopathy or is concealed in different types of LN. . Therapies targeting podocytes have a higher remission rate in LN patients with severe podocyte injury. . Lupus podocyte injury should be added to the ISN/ RPS (International Society of Nephrology and Renal Pathology Society) system for guiding therapy. 
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Supplementary data are available at Rheumatology Online.
